3 US Growth Stocks With Strong Balance Sheets And Earnings Focus

With inflation pressures moving differently across regions, central banks adjusting policy and energy prices adding another layer of uncertainty, many investors are looking for stocks where analysts still expect solid earnings growth and balance sheets that can cope with changing conditions. The Healthy high growth potential screener focuses on exactly that combination, highlighting companies where consensus points to strong earnings growth over the next 3 years and financial positions viewed as acceptable. In this article, you will see 3 of the best stocks from this screener to consider for further research as part of a growth focused watchlist.

Overview: Guidewire Software provides a suite of software and cloud services that help property and casualty insurers run core operations such as policy administration, claims handling, billing, pricing, and customer data management. Its platform also offers analytics, machine learning, and digital engagement tools so insurers can design products, assess risk, and interact with customers more efficiently.

Operations: Guidewire generates about US$1.4b in revenue, all from Software & Programming, with most sales coming from the United States at US$914.2m, followed by EMEA, Canada, APAC, and other Americas.

Market Cap: US$9.26b

Guidewire Software stands out for growth focused investors because its core business is tied to insurers upgrading to cloud based platforms and AI driven tools. This shift is already feeding into strong annual recurring revenue and recent double digit revenue growth in Q3 2026. Earnings have moved into consistent profitability with net margins now above 10%. At the same time, cloud migrations, AI products like ProNavigator, and high profile go lives with insurers such as Santam and Ethias indicate potential for further scaling. The flip side is a rich valuation, heavy reliance on external funding, and recent insider selling, which all call for careful monitoring rather than blind optimism, especially as the company executes its cloud transition and manages global expansion risks.

Guidewire Software’s shift to cloud and AI tools is accelerating, but the real story sits in how analysts see that playing out in future earnings and margins. That is exactly what the analyst forecasts for Guidewire Software starts to unpack.

Overview: Veeco Instruments supplies the complex equipment that chipmakers and electronics manufacturers use to build advanced semiconductors and thin film components, from logic and memory chips to power electronics and photonics devices. Its tools support processes like laser annealing, etching, and various deposition methods that are essential for AI data centers, high speed communications, and next generation consumer electronics.

Operations: Veeco generates about US$655.3m in revenue from semiconductor and thin film process equipment, with most sales coming from the Rest of APAC at US$360.6m and China at US$130.9m, followed by the United States and EMEA.

Market Cap: US$4.86b

Veeco Instruments offers investors a focused way to get exposure to semiconductor equipment tied to AI, advanced packaging, and high speed optical connections, but with a very real execution bar. On one hand, the company is winning sizable multi product orders above US$250m and securing qualifications for tools like its LUMINA+ MOCVD and NSA500 systems, which points to customer confidence in its technology and potential for strong revenue growth. On the other hand, earnings recently came under pressure, with profit margins at 3.5%, a recent loss in Q1 2026, and all liabilities funded by higher risk sources, while the stock trades above some valuation estimates and has seen insider selling. The key issue for investors is whether Veeco’s growth in AI infrastructure and compound semiconductors will be sufficient to offset these risks and support the earnings forecasts currently in focus.

Veeco Instruments’ AI and compound semiconductor exposure is accelerating, yet recent margin pressure and higher risk funding sources raise big questions. Get the full context in the 2 key rewards and 4 important warning signs

Overview: Legend Biotech develops and commercializes cell therapies for cancer, led by its CAR-T treatment cilta-cel (marketed as CARVYKTI) for multiple myeloma. It is building a broader pipeline that targets blood cancers and solid tumors across the United States, China, and Europe.

Operations: Legend Biotech generates about US$1.1b in biotechnology revenue, with around US$856.9m from the United States, US$254m from markets outside the US, and US$28.1m from China.

Market Cap: US$6.23b

Legend Biotech attracts growth-focused investors because CARVYKTI is already supporting US$1.1b in biotechnology revenue. Early data from programs such as LB2501 and LB2102 point to a second wave of potential therapies. The company is still reporting losses, but recent quarters show revenue above US$300m and a smaller net loss, and management has discussed moving toward adjusted profitability. At the same time, Legend is closely tied to a single commercial product, relies on higher-risk funding, and issued US$225m of new equity at US$29.35 per ADS, which means dilution and continued dependence on partners such as Janssen and Novartis. A key consideration for investors is whether the current valuation and analyst expectations reflect both that concentration risk and the scale of the multiple myeloma opportunity.

Legend Biotech’s accelerating CARVYKTI story and early pipeline hints suggest investors might be missing how expectations are shifting around future revenue, margins, and dilution risk. The analyst forecasts for Legend Biotech starts to reveal these changes.

The three stocks covered here are only a starting point. The full Healthy high growth potential screener surfaces 251 more companies where analysts expect strong earnings growth and acceptable financial positions, each with its own story. Use Simply Wall St to identify and analyze the specific catalysts, financial strengths, and earnings narratives that matter to you so you can focus on the highest conviction ideas from that wider list.

Take Control of Your Investment Journey

If Guidewire Software or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen.
Once you’ve made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates.
Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives.
By uncovering hidden catalysts and risks early, you’ll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before Others Do?

Some of the most interesting ideas appear while many investors are still focused on yesterday’s winners. Before momentum changes and puts them out of reach, review these fresh lists and consider your next steps.

• Spot companies with strong cash positions and limited debt pressure by running the curated list of solid balance sheet and fundamentals (48 results) so you are focusing on sturdier opportunities when markets turn.
• Look for income ideas that target yields above typical savings rates by reviewing the hand picked 8 dividend fortresses before yields change and preferred entry points are no longer available.
• Explore the shift toward automation by checking the carefully filtered 31 robotics and automation stocks while many of these businesses remain less widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com